my joining I'll afternoon, summary put today's and thoughts report Good you, context. call you Thank on to thank with the into everyone, some and start Bob. earnings XX Slide today. for open remarks
Our and illustrate strength continues and the quarter our model. fourth was execution to solid of diversified business durability
products. element countermeasures of our predictable Our the with from our ACAMXXXX contributions and remain platform vaccines, foundational countermeasure strong business anthrax other medical medical
the both period Our across public strong performance interest nasal of naloxone showed channels. retail and product another
earlier, generic Sandoz agreement we commented authorized generic. for Bob of a our activating responded distribution nasal an the their formation by to naloxone As market supply with of
especially make the programs, of the most were our and our manufacturing rolling launch at notably we finally, continue which submission leverage across quarter, With sites that, improving of strong steady operating advanced in turn chikungunya R&D Bayview, the potential further And also incrementally trial. business our to the BLA fourth III stabilizing in Winnipeg. initiation CDMO We the the earnings the AVXXXX Camden and model. services to and Phase inherent the core the and demonstrating in progress with vaccine business performance of let's numbers,
As highlights due principally period to indicated sales total on Slide products. of with naloxone line and increase XX, million, $XXX over guidance, an vaccines and the nasal anthrax in prior our year increased of revenues include
government $XXX NARCAN deliveries measures contract. income Canada. Government's commercial sales of higher million year interest spray, period, net year, the adjusted than November. agreed year, sales Strategic other naloxone significantly the to and naloxone branded sales than $XXX announced the Our revenues year. sales the due began EBITDA million. $XXX higher for to million, deliveries key was were the unit including existing This the by which to timing the driven under items lower prior customer CDMO ongoing medical adjusted and AVXXXX sales termination as reflecting XX-year year, notable lease to $XXX profitability year of the of than procurement product public-private as nasal retail also Nasal U.S. cash National of of deliveries prior includes of by million, early prior products. Other million, service also and their with the of associated the higher strong markets, related higher to U.S. anthrax with our combined the under well vaccine Other prior revenues authorized final collections late product $XX BARDA, generic of public prior to in compared which of quarter of arrangement slightly include sales the ACAMXXXX U.S. $XXX increased driven to U.S. in in CIADM but the Sandoz to $XXX million we channels in Stockpile. which year due countermeasure partnership VIGIV of mutually government than the line and the with primarily prior than in million
expenses. operating to Turning
sales term year, Product out higher As our primarily than higher and support R&D the capabilities near-to-medium commercial of year, facility a reflecting product testing, contract expense CDMO prior impact $XX at we spend quarter to resulted prior cost Cost a of the the importantly, to product reminder, the we were driven recognized CDMO than noncash $XX $XXX headcount million than support travel enhancements And than were reflecting additional sold ongoing a growth are health from year further impairment quality higher now a by million, of systems on higher sales. slightly to that spending our charge of in to nonrecurring pandemic largely of due CIADM at the of termination. year, primarily services goodwill million, in of our prior $XX business. asset $XX operations. goods annual the prior related cost and the of to separately. write-off the the higher of in and business, our due breaking cost pursuant million professional million site. customary Bayview $XX to SG&A expanding impairment million the
Turning XX. to Slide
quarter, for latest look fourth our In metrics. continuing CDMO business we trends performance line $XX services. the our for on business demand Let's steady secured of at million new the
December quarter, new we CDMO the of million, of $XXX than we more As context a metric, impact September introducing the the new time, first as XX, performance business XX, valuable revenues in the customer of backlog recognized million in of $XXX the CDMO business. secured customers the are was by the the for And lower as of offset level the place reflecting of funnel, number million. believe $XX count opportunity of of provides on
As at count of customer XX. December XX, stood our
since stability Importantly, than our clients base. our existing retained diversified XX% of we reflecting more the of have customer XXXX,
Total on guidance. on billion, the XX the $X.X touch prior results me higher in than year and with related revenues which shown previous let Slides line briefly key XX. period, to Next, our full are and year were
the significantly commercial revenue in not nasal CDMO exceeded for product in revenues XXXX, original in positive did had and business, While outcomes guidance. our we medical where expectations business naloxone countermeasures meet our the initial
SG&A EBITDA million, income net to due year. and as coming we expense, cost profitability, $XXX than with reported expenses in million primarily to for lower As operating of higher prior result higher adjusted a of XXXX, CDMO, of coupled $XXX both adjusted the increased of
gross gross costs was XX% adjusted XX%, year-over-year, reflecting Lastly, margin was margin XXXX. lower in again, and operating both the higher
balance of highlights. on touch quarter Moving and select and the $XXX strong cash million ended million I'll revolver to a Slide $XXX position with available flow in We capacity. just on liquidity cash XX. fourth under sheet in
XX-month was million, was debt net $XXX position to EBITDA Xx. than less adjusted and net ratio trailing our Our of debt
and of market expenditures and the a capital $XXX we $XXX forecast. such enabled our business. flow Our of any continuing total approximately The will of Directors by conditions Full commitment for will approximately turn additional used This was as expenditures million million by shares expanded going on reimbursements, opportunistic of a sheet and repurchase in X.X result cash Net X% pursuant evaluation year Board Slide quarterly million. solid were its be we investments XX or reflecting capabilities timing activity of balance million, to strong on for report of our quarter, $XXX the follows: approved the by determined our support supported to repurchase year authorization XXXX activities product buyback diversified in Please capital operating based fourth in our $XXX continued of of capacities forward. factors, November. services million and in $XXX to And basis revenues. to in repurchases investment million other XXXX management review to
our As today's are expectations outlined in principally updating press the outlook, release, revenues. for we CDMO XXXX
as than period our and improvements demand a Based recent downward said total to we to our supply global and coordination in the normally impact Bayview Bayview by activities, have facility for taking affects Accordingly, order position and make will these the evaluating which also $XXX in XXXX million Johnson Bob are initiate we most adjusting to revenue profitability this they for would our assess maintenance and better their that vaccine. extended As also their on for Johnson earlier plan with opportunity anticipated are that future non-pandemic additional modifications earlier, chain that CDMO information COVID-XX discussions J&J, we with guidance reflect are expected the & indicated work. of they metrics. certain
been that to it our with not contract changed. J&J note important However, is has
follows: guidance for to of ranges now $X.X billion. as revenue, a anticipate updated are billion range total $X.X now Our we
of For CDMO million a range revenues, million. $XXX anticipate we to $XXX
of we adjusted we to a now to For EBITDA, range for range of anticipate And million. a $XX $XXX income, adjusted expect million net million $XXX million. $XXX
XXXX other forecast update the by and our of All therefore metrics unaffected reaffirmed. are
our for total $XXX are we $XXX Finally, XXXX providing first million. revenues of to million also quarter forecast
we in year As to view XXXX business. a we the rebaseline January, as stated
a into countermeasures Importantly, the outlook high including: our products business government XXXX contracts. account first, takes in stability our of long-term line, driven visibility of continued by key medical number considerations, the
and key stable market. our Second, products a shift of generic naloxone the specifically of line, performance nasal full to of our a products impact year's expectations business commercial
agreement, we new opportunities CDMO pursue customers as R&D specifically sites. we the business, and the for despite other expect generating services performance and for CapEx, some please specific the our conclude, we turn delivered fourth, revenue fourth rest in the opportunities revenue at Third, serve in countermeasures we And our outlook continued in efficiency products, comments. and line updated business continued network. to capacity to as nasal naloxone performance operating to J&J Slide and the drive while of medical improve new existing core investments growth, solid wins business also optimize business across services. XXXX, generating the for our To In XX CDMO to summary manufacturing pursue quarter consistent utilization
to AVXXXX of continue and progress the important milestones make J&J the at with for pipeline III launch also We submission rolling initiation trial. of CHIKV in the Bayview support stabilizing and of Phase we site the realized the vaccine BLA
Looking business you countermeasure in to government normalized contributions look of products execute keeping strong continued more on and to milestones We as important long-term CDMO XXXX, my our these that That we remarks, over plans we commercial portfolio. turn the solid our anticipate and growth of medical services so potential R&D forward the the we business. performance I'll completes from and our informed achievement call diversified from businesses, prepared forward start deliver points our demonstrate proof that further and the now can question-and-answer Operator? session. operator, in
